AR089852A1 - Anticuerpos anti-asic-1 y usos de los mismos - Google Patents

Anticuerpos anti-asic-1 y usos de los mismos

Info

Publication number
AR089852A1
AR089852A1 ARP130100280A AR089852A1 AR 089852 A1 AR089852 A1 AR 089852A1 AR P130100280 A ARP130100280 A AR P130100280A AR 089852 A1 AR089852 A1 AR 089852A1
Authority
AR
Argentina
Prior art keywords
antibodies
asic1
acid
cells expressing
asic
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR089852A1 publication Critical patent/AR089852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP130100280 2012-01-31 2013-01-30 Anticuerpos anti-asic-1 y usos de los mismos AR089852A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
AR089852A1 true AR089852A1 (es) 2014-09-24

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100280 AR089852A1 (es) 2012-01-31 2013-01-30 Anticuerpos anti-asic-1 y usos de los mismos

Country Status (33)

Country Link
US (3) US9150648B2 (https=)
EP (2) EP2809681B1 (https=)
JP (1) JP6302844B2 (https=)
KR (1) KR102111941B1 (https=)
CN (1) CN104093738B (https=)
AR (1) AR089852A1 (https=)
AU (1) AU2013215254B2 (https=)
CA (1) CA2862332C (https=)
CL (1) CL2014002019A1 (https=)
CO (1) CO7020877A2 (https=)
CY (2) CY1121368T1 (https=)
DK (2) DK3453723T3 (https=)
EA (1) EA028647B1 (https=)
ES (2) ES2886123T3 (https=)
HR (2) HRP20190358T1 (https=)
HU (2) HUE056335T2 (https=)
IL (2) IL233410A0 (https=)
IN (1) IN2014CN04645A (https=)
JO (1) JO3547B1 (https=)
LT (2) LT2809681T (https=)
MX (1) MX358518B (https=)
MY (1) MY168748A (https=)
NZ (1) NZ626242A (https=)
PH (1) PH12014501613B1 (https=)
PL (2) PL2809681T3 (https=)
PT (2) PT3453723T (https=)
RS (2) RS58439B1 (https=)
SG (1) SG11201403222UA (https=)
SI (2) SI3453723T1 (https=)
SM (1) SMT202100628T1 (https=)
TW (1) TWI591073B (https=)
UY (1) UY34603A (https=)
WO (1) WO2013116296A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
JP2017513854A (ja) 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
EP4707303A2 (en) 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
CN111936517B (zh) * 2018-01-26 2025-04-18 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
AU2019449475A1 (en) * 2019-06-04 2022-01-06 Shanghaitech University Affinity-maturated anti-ASIC1a antibodies
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
JP2024083709A (ja) * 2022-12-12 2024-06-24 ａｒｔｉｅｎｃｅ株式会社 コート剤、シートおよび成形体
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ATE347596T1 (de) 1997-10-29 2006-12-15 Univ Mcgill Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
PT1527100E (pt) * 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
WO2005025518A2 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
JP2007530664A (ja) 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CA2763671A1 (en) * 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
JP5307708B2 (ja) * 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP5382692B2 (ja) * 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
WO2008007131A2 (en) * 2006-07-14 2008-01-17 Medical Research Council Treatment for demyelinating disease
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DE602008002913D1 (de) 2007-04-03 2010-11-18 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20110262395A1 (en) * 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
CN104093738A (zh) 2014-10-08
RS58439B1 (sr) 2019-04-30
BR112014018651A2 (pt) 2017-07-04
HUE042531T2 (hu) 2019-07-29
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
EP3453723B1 (en) 2021-08-11
JO3547B1 (ar) 2020-07-05
US10513557B2 (en) 2019-12-24
TWI591073B (zh) 2017-07-11
DK2809681T3 (en) 2019-03-11
AU2013215254A1 (en) 2014-07-03
EP3453723A2 (en) 2019-03-13
UY34603A (es) 2013-07-31
LT2809681T (lt) 2019-02-11
KR102111941B1 (ko) 2020-05-18
WO2013116296A1 (en) 2013-08-08
MY168748A (en) 2018-11-30
SI3453723T1 (sl) 2021-11-30
PL3453723T3 (pl) 2022-01-03
CL2014002019A1 (es) 2015-01-16
TW201335182A (zh) 2013-09-01
ES2886123T3 (es) 2021-12-16
US20130195878A1 (en) 2013-08-01
DK3453723T3 (da) 2021-09-13
MX358518B (es) 2018-08-24
SG11201403222UA (en) 2014-07-30
US9150648B2 (en) 2015-10-06
US20160002332A1 (en) 2016-01-07
MX2014008541A (es) 2014-10-24
CY1124778T1 (el) 2022-11-25
EA201491452A1 (ru) 2014-11-28
IL233410A0 (en) 2014-08-31
EP2809681B1 (en) 2018-12-05
US20180222976A1 (en) 2018-08-09
JP6302844B2 (ja) 2018-03-28
EP3453723A3 (en) 2019-04-10
RS62454B1 (sr) 2021-11-30
HUE056335T2 (hu) 2022-02-28
ES2707599T3 (es) 2019-04-04
JP2015508063A (ja) 2015-03-16
CA2862332A1 (en) 2013-08-08
CA2862332C (en) 2021-05-18
IL254416A0 (en) 2017-11-30
PL2809681T3 (pl) 2019-05-31
HRP20211541T1 (hr) 2021-12-24
PH12014501613A1 (en) 2014-10-13
CN104093738B (zh) 2018-05-18
CY1121368T1 (el) 2020-05-29
PT2809681T (pt) 2019-02-18
IL254416B (en) 2018-03-29
AU2013215254B2 (en) 2017-08-31
PH12014501613B1 (en) 2014-10-13
PT3453723T (pt) 2021-09-07
KR20140125363A (ko) 2014-10-28
SMT202100628T1 (it) 2022-01-10
EP2809681A1 (en) 2014-12-10
NZ626242A (en) 2017-02-24
HK1199269A1 (en) 2015-06-26
IN2014CN04645A (https=) 2015-09-18
HRP20190358T1 (hr) 2019-04-05
SI2809681T1 (sl) 2019-04-30
LT3453723T (lt) 2021-09-10

Similar Documents

Publication Publication Date Title
AR089852A1 (es) Anticuerpos anti-asic-1 y usos de los mismos
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX2021001878A (es) Metodos y composiciones para mejorar las celulas t reguladoras cd4+.
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2015007846A (es) Anticuerpos anti-b7-h4 humana y sus usos.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
MX2014011623A (es) Metodos y composiciones para tratar inflamacion.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
MX2015003701A (es) Composiciones para tratamiento.
BR112016028895A2 (pt) composições biofotônicas termofixas e usos destas
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
CL2015003563A1 (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos.
MX395106B (es) Celulas t alogenicas específicas de wt1 y usos de las mismas.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.

Legal Events

Date Code Title Description
FG Grant, registration